Clinical Trials Logo

Mental Disorders clinical trials

View clinical trials related to Mental Disorders.

Filter by:

NCT ID: NCT05664594 Recruiting - Schizophrenia Clinical Trials

State Representation in Early Psychosis - Project 4

STEP (P4)
Start date: July 31, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to examine state representation in individuals aged 15-45 who have been diagnosed with a psychotic illness, as well as young adults who do not have a psychiatric diagnosis. State Representation is our ability to process information about our surroundings. The investigators will complete a clinical trial examining two paradigms of cognitive training.

NCT ID: NCT05659498 Recruiting - Clinical trials for Cardiovascular Prevention

Cardiac Rehabilitation for Cardiovascular Risk Reduction in People With Severe and Persistent Mental Illness

Start date: December 14, 2022
Phase: N/A
Study type: Interventional

The goal of this prospective, randomized trial is to explore the link between cardiovascular disease and mortality in individuals with severe and persistent mental illness (SPMI). The main question it aims to answer is: Is a primary prevention cardiac rehabilitation intervention feasible and effective at reducing cardiovascular risk in people with a primary psychotic disorder or bipolar disorder?" Participants will undergo a multi-component primary prevention intervention program. Researchers will compare with a control group to see if cardiovascular risk reduction is attained.

NCT ID: NCT05658068 Recruiting - Suicide Clinical Trials

Systems Aligning for Equity (SAFE) Spaces

SAFE Spaces
Start date: April 23, 2022
Phase: N/A
Study type: Interventional

The goal of this 2-arm cluster randomized clinical trial is to test whether an evidence-based staff training and coaching model specifically designed as a response to legal system-involved youths' and frontline staff's mental health needs can improve the safety and suicide outcomes, mental health challenges, and wellness and facility climate for youth and staff in facilities assigned to the intervention condition. Staff in facilities assigned to the intervention are eligible to receive evidence-based programming in suicide detection and prevention (Shield of Care; SOC) and wellness skill-building (Skills for Life) through training and personalized coaching. Multiple training sessions will be offered to small groups of staff in-person in residential facilities and paired with personalized in-person and virtual coaching. Staff and youth in all facilities will be asked to complete periodic surveys assessing experiences in the facility, suicide and safety knowledge and risk, and their mental health and wellness. Researchers will compare outcomes of staff in youth in facilities assigned to the intervention compared to facilities in the training-as-usual condition.

NCT ID: NCT05647980 Recruiting - Clinical trials for Mental Disorders, Severe

Transmural Collaborative Care Model for CVRM and Medication Review for Patients Using Antipsychotics

TACTIC
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient. A transmural collaborative care model for cardiovascular risk management and medication review for patients using atypical antipsychotics in general practice (TACTIC) was developed. This trial aims to assess the effectiveness of TACTIC regarding predicted cardiovascular risk and mental quality of life.

NCT ID: NCT05646095 Recruiting - Child Development Clinical Trials

A Trauma-Informed Sleep Intervention for Children in Foster Care

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Sleep disturbances are pervasive and impairing among children who spend time in foster care but not a single prevention or intervention program for this fragile group targets sleep health. Poor sleep undermines effective self-regulation and stable biological rhythms, amplifying the negative impacts of early adversity/trauma on immediate and long-term functioning. Consistent with evidence that optimizing sleep is critical for trauma recovery, the investigators will adapt cognitive-behavioral treatment for pediatric insomnia for children placed in or adopted from foster care to evaluate child outcomes and target mechanism engagement and explore implementation barriers and supports.

NCT ID: NCT05639881 Recruiting - Mental Disorder Clinical Trials

Enhancing Immune Health Randomized Controlled Trial

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This study tests a psychosocial intervention to improve immune health literacy and behaviors among adults with mental illnesses.

NCT ID: NCT05639855 Recruiting - Clinical trials for Mental Health Disorder

Study on Mental Health-related Stigma

Start date: September 5, 2021
Phase: N/A
Study type: Interventional

Mental disorders are currently among the main causes of disability worldwide. For this reason, various national and international organisations include the promotion of mental health among their strategic actions, with special emphasis on the fight against stigma. Evidence shows that stigma has a negative impact on the process of recovery and participation of people with mental disorders. The general aim of this study is to find out about the attitudes of university students at the University of A Coruña towards people with mental disorders and specifically to intervene with students of the Bachelor's Degree in Occupational Therapy to assess whether taking part in a Mental Health Literacy Programme changes these attitudes.

NCT ID: NCT05637320 Recruiting - Anxiety Disorders Clinical Trials

Big Feelings: A Study on Children's Emotions in Therapy

Start date: October 1, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about how psychotherapy works for children and adolescents aged 8 - 15 with anxiety, depression, trauma, or disruptive behaviour. The main question it aims to answer is: • Is the biobehavioural regulation of negative emotion a transdiagnostic mechanism of treatment response in psychotherapy for children with anxiety, depression, trauma and/or disruptive behaviour? Children and their parents will be randomly assigned to an evidence-based, transdiagnostic treatment (the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems; MATCH-ADTC) or a waitlist control condition. Participants in both groups will complete a baseline assessment, weekly measures consisting of brief symptom scales and medication tracking, and quarterly assessments every 3 months. Following the intervention/waitlist period, our team will conduct post-test assessments. All assessments, except for the weekly surveys, will consist of symptom scales, clinical interviews, experimental tasks and physiological measures.

NCT ID: NCT05633940 Recruiting - Mental Disorder Clinical Trials

The Effects of Primary Care Behavioral Health in Primary Care in Sweden

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The novel multi-professional service delivery model "Primary Care Behavioural Health" (PCBH) has been suggested as an effective way to integrate behavioural health services into routine primary care to overcome the growing problems with psychosocial and mental health problems in primary care. In this multicenter mixed-methods pragmatic clinical trial, the implementation of PCBH in routine primary health care in a region in Sweden is investigated.

NCT ID: NCT05622201 Recruiting - Clinical trials for Schizophrenia Spectrum and Other Psychotic Disorders

A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults

RCT-RITS
Start date: March 21, 2023
Phase: Phase 2
Study type: Interventional

Immunological factors are assumed to be determinants for some psychiatric disorders, thus anti-inflammatory drugs may be helpful. However, studies on such treatments are scarce. An inflammatory modulating drug rituximab, cluster of differentiation antigen 20 antibodies (anti-CD20 antibodies), is a standard treatment for e.g. multiple sclerosis. The investigators aim to test rituximab in a randomised placebo-controlled double-blinded, add-on treatment trial in 120 participants (18-55 years) with schizophrenia spectrum disorder. Sampling from blood for analyses of inflammatory mediators are investigated at gene and protein levels and resting state functional magnetic resonance imaging (rsfMRI) and lumbar puncture are optional. Biomarkers will be investigated in relation to treatment response. Family member(s) to the patient and the patient (separate) will be asked to participate in a qualitative interview by an independent researcher after 3 months.